Optimizing Treatment Outcomes in HR+ Breast Cancer

Video

An overview of unmet needs surrounding current treatment patterns for early-stage HR+ breast cancer.

Kristie Kahl: What are some of the unmet needs in the treatment of early stage hormone receptor–positive breast cancer?

Reshma L. Mahtani, DO: Although we’ve made considerable progress, we have quite a bit of work to do. We have data with CDK4/6 inhibitors in the adjuvant setting, and we’re trying to understand why we’re seeing seemingly different results from some of these agents, as well as learning whether the differences that we have seen will hold up with time. That’s an important area that requires further clarification.

It’s critical for us to get a better understanding of what’s happening in the younger patient population that is getting a benefit from chemotherapy, and whether it’s really the benefit of the chemotherapy or the induction of ovarian suppression. That’s going to be a really important area for us to clarify. Perhaps it will result in more widespread use of ovarian suppression, or we’ll identify that it really is a benefit of chemotherapy and that these patients should be treated. This is certainly an unmet need.

It’s also really important to understand the toxicities associated with our therapies and how to better mitigate those toxicities, especially endocrine therapy. Many patients suffer with adverse effects on these treatments. While it’s great to see the availability of a tool such as the Breast Cancer Index come into more widespread use to spare women some of the toxicities, for those women where we identify that there really is a benefit, we need to do better in helping them manage some of these more common adverse effects because they significantly impact quality of life.

Kristie Kahl: Absolutely. Thank you so much, Dr Mahtani. I hope that you found this information to be valuable in your clinical practice. Thank you all for watching this CancerNetwork® OncView program from MJH Studios™.

Transcript edited for clarity.

Related Videos
Ghayas C. Issa, MD, an expert on acute myeloid leukemia
Ghayas C. Issa, MD, an expert on acute myeloid leukemia
Administering immunotherapy following surgery in patients with early-stage triple-negative breast cancer does not appear to be as effective as beginning with neoadjuvant treatment, says Peter Schmid, MD, PhD.
Heather A. Parsons, MD, MPH, says she is excited about HER2 as a biomarker and investigating the biology of metastatic breast cancer with a minimally invasive liquid biopsy platform.
Exercise and healthy lifestyles can lower the risk of cancer or the symptoms of cancer treatment despite having genetic dispositions, said Neil M. Iyengar, MD.
The Hispanic Breast Cancer Clinic at Northwestern Memorial Hospital includes a social worker, nurse practitioners, a medical oncologist, a radiation oncologist, and surgeons, says Claudia Tellez, MD.
The goal of creating the Hispanic Breast Cancer Clinic at Northwestern Memorial Hospital is to establish a safe space for Hispanic patients, says Claudia Tellez, MD.
Related Content
Treatment with atezolizumab among patients with HER2-positive breast cancer in the phase 3 APTneo Michelangelo trial produces no major tolerability issues, says Luca Gianni, MD.

Atezolizumab Combo Numerically Improves pCR in HER2+ Operable Breast Cancer

December 9th 2023
Article

Treatment with atezolizumab among patients with HER2-positive breast cancer in the phase 3 APTneo Michelangelo trial produces no major tolerability issues, says Luca Gianni, MD.

Rebecca M. Shulman, MD, and Zachary Kiss, DO, discuss findings from a study evaluating differences in outcomes with radiotherapy and disease characteristics of patients with breast cancer harboring BRCA mutations compared with those without mutated disease.

Experts Discuss Differences in Radiotherapy Outcomes in BRCA+ Breast Cancer

October 30th 2023
Podcast

Rebecca M. Shulman, MD, and Zachary Kiss, DO, discuss findings from a study evaluating differences in outcomes with radiotherapy and disease characteristics of patients with breast cancer harboring BRCA mutations compared with those without mutated disease.

Latin American patients appear more likely to be diagnosed with aggressive early-stage breast cancer based on factors including metabolics and genetics, according to findings from the FLEX study.

Metabolism, Genetics May Impact Tumor Biology in Breast Cancer Populations

December 8th 2023
Article

Latin American patients appear more likely to be diagnosed with aggressive early-stage breast cancer based on factors including metabolics and genetics, according to findings from the FLEX study.

Rakhshanda Rahman, MD, FRCS, FACS, emphasizes educating patients and physicians on the potential risks and benefits of new approaches and technologies involved in the de-escalation of breast cancer treatment.

Oncology On-The-Go Podcast: De-escalating Breast Cancer Treatment

May 8th 2023
Podcast

Rakhshanda Rahman, MD, FRCS, FACS, emphasizes the importance of educating patients and physicians on the potential risks and benefits of new approaches and technologies involved in the de-escalation of breast cancer treatment.

Investigators observe no new safety signals with trastuzumab emtansine as a treatment for HER2-positive breast cancer after 8 years of follow-up in the phase 3 KATHERINE study.

T-DM1 Improves OS/iDFS Vs Trastuzumab in HER2+ Breast Cancer

December 8th 2023
Article

Investigators observe no new safety signals with trastuzumab emtansine as a treatment for HER2-positive breast cancer after 8 years of follow-up in the phase 3 KATHERINE study.

Future research may focus on the relationship between neoadjuvant chemotherapy regimens, pathologic complete response, and whole transcriptome changes in patients with hormone receptor–positive, HER2-negative early-stage breast cancer.

Profiling Tests May Predict Chemo Efficacy in Early-Stage Breast Cancer

December 8th 2023
Article

Future research may focus on the relationship between neoadjuvant chemotherapy regimens, pathologic complete response, and whole transcriptome changes in patients with hormone receptor–positive, HER2-negative early-stage breast cancer.